Top 10 Buprenorphine (Subutex) Generic Manufacturers in Brazil
The Brazilian pharmaceutical market is one of the largest in Latin America, with a growing demand for generic medications, including buprenorphine, a medication primarily used to treat opioid addiction and pain. In Brazil, the market for buprenorphine has expanded significantly, with a reported growth rate of approximately 10% annually in recent years. According to the Brazilian Association of Pharmaceutical Industries (ABIFINA), the market size for generics in Brazil reached around BRL 27 billion in 2022, emphasizing the importance of local manufacturers in providing affordable healthcare solutions.
1. Eurofarma Laboratórios
Eurofarma is one of Brazil’s largest pharmaceutical companies, with a robust portfolio that includes buprenorphine. The company generates an estimated BRL 4 billion in annual revenue and holds a significant share of the Brazilian generic market. Eurofarma’s production facilities are certified by international health authorities, ensuring high-quality standards.
2. Aché Laboratórios Farmacêuticos
Aché is a prominent player in the Brazilian pharmaceutical industry, with a strong focus on generics. The company has a production capacity of over 2 billion units annually and reported a market share of approximately 10% in the generic segment. Aché’s buprenorphine products are widely recognized for their efficacy and affordability.
3. EMS S/A
EMS is one of the largest generic pharmaceutical manufacturers in Brazil, with a diverse product range, including buprenorphine. The company has a production capacity surpassing 1 billion units per year and holds around 12% of the Brazilian generics market. EMS is known for its commitment to quality and innovation in drug formulation.
4. União QuÃmica Farmacêutica Nacional S/A
União QuÃmica is a key player in the Brazilian pharmaceutical market, specializing in generics and branded medications. The company has an annual production capacity of 1.5 billion units and a market share of approximately 8% in the generics sector. Their buprenorphine products are well-regarded within the healthcare community.
5. Farmacêutica do Brasil (Farbrazil)
Farbrazil is a significant manufacturer of generic medications, including buprenorphine. The company produces around 500 million units annually and has a growing presence in the Brazilian market, capturing about 5% of the generics market share. Farbrazil focuses on affordability and accessibility for patients.
6. Cristália Produtos QuÃmicos Farmacêuticos
Cristália is known for its extensive research and development initiatives in the pharmaceutical sector. The company produces over 600 million units of various medications each year, with a notable share in the buprenorphine segment. Cristália’s market share in generics is approximately 6%, reflecting its strong reputation in the industry.
7. Laboratórios Teuto Brasileiro S/A
Teuto is a well-established manufacturer in Brazil, offering a wide range of generic medications, including buprenorphine. With an annual production capacity of over 800 million units, Teuto holds around 4% of the generics market. The company is recognized for its commitment to quality and patient care.
8. Medley Farmacêutica
Medley, a subsidiary of the global pharmaceutical company Sanofi, has a significant presence in the Brazilian generics market. The company produces approximately 700 million units annually and has a market share of about 3%. Medley’s focus on buprenorphine contributes to its reputation for producing effective and reliable medications.
9. Laboratório São Paulo
Laboratório São Paulo specializes in the production of generic drugs, including buprenorphine. The company has an estimated annual production capacity of 300 million units and a market share of around 2%. Their commitment to quality and competitive pricing makes them a notable player in the generics market.
10. Hipolabor Farmacêutica
Hipolabor is one of Brazil’s emerging manufacturers of generic medications, with a focus on affordability and quality. The company produces approximately 400 million units per year, capturing about 2% of the generics market. Hipolabor’s buprenorphine products are increasingly recognized in the healthcare sector.
Insights
The Brazilian market for buprenorphine generics is poised for continued growth, driven by increased demand for affordable healthcare solutions and the expansion of local manufacturers. The generic segment in Brazil is expected to grow at a compound annual growth rate (CAGR) of around 10% over the next five years, with the total pharmaceutical market projected to reach BRL 60 billion by 2026. As local manufacturers enhance their production capabilities and invest in innovative solutions, the competition in the buprenorphine market will likely intensify, ultimately benefiting patients and healthcare providers across Brazil.
Related Analysis: View Previous Industry Report
